Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of inhaled MD-711 (treprostinil) in pulmonary hypertension associated with interstitial lung disease
jRCT2051210016Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of treprostinil in pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension (PH) and Pulmonary hypertension associated with lung diseases with mixed restrictive and obstructive pattern (PH-Mixed), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoints: Rate of change in PVRI and Amount of change in 6MWD. Started Jul 2021; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)pulmonary hypertension (PH)Pulmonary hypertension associated with lung diseases with mixed restrictive and obstructive pattern (PH-Mixed)
Beyond the preview
Go deeper on jRCT2051210016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210016.